http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
-
Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
-
Rezolute Inc. (RZLT) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
-
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
-
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
-
Rezolute (RZLT) Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE
-
Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
-
Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
-
Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
-
Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
-
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism
-
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism
-
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
-
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
-
Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME
-
Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME
-
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
-
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
-
Rezolute Added to Russell Microcap® Index
-
Rezolute Added to Russell Microcap® Index
-
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
-
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
-
Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs
-
Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board
-
Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress
-
Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit
-
Rezolute (RZLT) Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema
-
Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema
-
Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners
-
Rezolute Inc. (RZLT) Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
-
Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
-
Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts
-
Rezolute to Participate in Upcoming Investor Conferences in March
-
Rezolute Reports Second Quarter Fiscal 2021 Financial Results
-
Rezolute Inc. (RZLT) Begins Phase 1 Study of RZ402
-
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
-
Rezolute Announces Change of Transfer Agent
-
Rezolute (RZLT) Announces FDA Clears its IND Application for RZ402
-
FDA Clears Rezolute’s IND Application for RZ402
-
Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
-
Rezolute Announces Uplisting to the Nasdaq Capital Market
-
Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq
-
Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors
-
Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
-
Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science
-
Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher
-
Rezolute Presents RZ358 Clinical Data-Validated Model of the Pharmacokinetics and Glycemic Response in Congenital Hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting
-
Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting
-
Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic
-
Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
